Effective pre-test discussion? A case note review Mel Ottewill & Dr Zoe Warwick SSHA Conference 2008.

Slides:



Advertisements
Similar presentations
For primary and secondary care settings
Advertisements

CLINICS AND COMMUNITY Dr Mags Portman.
Sexually transmitted infections: epidemiological evidence of need Dr Kirsty Foster Consultant in Health Protection Public Health England Centre, North.
Factors Associated with Potential Exposure to and Transmission of HIV in a Probability Sample of Men Who Have Sex with Men Devon D. Brewer Matthew R. Golden.
Perspectives on Outreach from the NYC Department of Health and Mental Hygiene Benjamin Tsoi, MD, MPH Bureau of HIV/AIDS Prevention and Control NYC Department.
Increased routine screening for syphilis and falling syphilis incidence in HIV positive and HIV negative men who have sex with men: implications for syphilis.
Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.
Cristin Muecke, RMOH Nick Scott, ED AIDS NB.  Why HIV testing remains important  Treatment as prevention  Discuss advantages/disadvantages of various.
BAME MSM Prevention Parminder Sekhon Executive Director of Programmes.
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
HIV Self-Sampling: Establishing a sustainable service
Opt-Out HIV Testing in the Denver STD Clinic Kees Rietmeijer, MD, PhD Denver Public Health Department American Society for Microbiology 107 th General.
Improving HIV case detection Steve Baguley Genitourinary physician, Aberdeen.
The case for increasing HIV testing in all medical settings 1.
A prioritisation tool for HIV testing in primary care in Leeds Duncan Cooper, Owen Brigstock-Baron, Brenda Fullard and Richard Dixon - NHS Leeds Antony.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
HIV and STI Department - Centre for Infections Reducing the burden of undiagnosed HIV infection Dr Valerie Delpech HIV & STI Department Centre for Infections.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Professor Graham J Hart PhD Sexual Health Promotion & HIV Prevention for HIV Positive MSM: Issues & Challenges Centre for Sexual Health & HIV Research.
Ecological Model for HIV Risk in MSM Stage of Epidemic Individual Community Public Policy Network Level of Risks Source: Baral and Beyrer, 2006.
HIV/AIDS Prevalence & Mortality Report, 2010 Minnesota Department of Health HIV/AIDS Surveillance System Minnesota Department of Health HIV/AIDS Surveillance.
BHIVA national clinical audit of HIV diagnosis Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical.
Community HIV testing for men who have sex with men (MSM) Will it decrease undiagnosed infection? Jonathan Roberts Liaison Health Adviser Brighton & Sussex.
Module 6: Routine HIV Testing of TB Patients. Learning Objectives Explain why TB suspects and patients should be routinely tested for HIV Summarize the.
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
HIV Infection Among Those with an Injection Drug Use*- Associated Risk, Florida, 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division.
HIV testing and diagnosis Dr Simon Ellis On behalf of the Audit & Standards Sub-Committee.
Monitoring the effects of ARV treatment programmes on prevention Gabriel Mwaluko 1, Mark Urassa,2, John Changalucha,2, Ties Boerma 3 1 TANESA Project,
Africans and HIV in the UK: an epidemiological perspective Nov 2006 Tim Chadborn On behalf of the HIV Reporting Section with special thanks to Julia Abernethy.
Universal HIV Testing Closing the Gap Peter A. Leone, MD Associate Professor of Medicine University of North Carolina Medical Director, NC HIV/STD Prevention.
BHIVA 2006 Gus Cairns. BHIVA 2006 – selected studies People with CD4s
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Immigration Removal Centres and HIV Joe Murray Policy Officer National AIDS Trust.
National Audit Group National Audit of Sexual Healthcare for People with HIV Infection National Audit Group British Association for Sexual Health & HIV.
HIV/STD Research Program Thailand MOPH – US CDC Collaboration Bangkok, Thailand IAS 2015 July 21, 2015: TUAC0302 HIV/STD Research Program Division of HIV/AIDS.
Alliance Discussion with Office of AIDS: November HIV/AIDS Surveillance Surveillance overview HIV Incidence Surveillance Second Surveillance Stakeholder.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014 Florida Department of Health HIV/AIDS Section Division of Disease.
ANC surveillance research Yusufu Kumogola, Emma Slaymaker, Raphael Isingo, Julius Mngara, Basia Zaba, John Changalucha and Mark Urassa TAZAMA / NACP seminar,
J. Frankis 1, K. Lorimer 1, M. Davis 2, C. Knussen 1, L. McDaid 3, P. Flowers 1 1 Glasgow Caledonian University, School of Health and Life Sciences, 2.
HIV and African M S M in England: A new wave of Challenge. Presented by Adebisi Alimi.
Sexual transmission of HIV amongst migrant populations in Europe: managing change in surveillance, interventions and prevention V.Delpech and Teymur Noori.
S. Sutherland, L. Byfield, N. Cooper National HIV/STI Programme, Ministry of Health Jamaica, West Indies.
2010 BASHH NATIONAL RE-AUDIT ON SEXUAL HISTORY TAKING A Sullivan, H McClean, C Carne, S Tayal, D Daniels September 2010.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
The case for HIV testing A presentation for the clinical team in your practice.
Martin Fisher Foundation: 14 September Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
1 MSM Sexual Health Summit August 20, 2012 HIV/STD Prevention and Care Branch Texas Department of State Health Services.
SEXUAL HEALTH: SCREENING, VACCINES AND REFERRALS Dr Kate Morton.
Research Study Gavin Bryce Health Promotion Specialist NHS Brighton and Hove Provider-initiated HIV testing in primary care.
The Prevalence of Chlamydia Infection in Youth Offenders in HMP/YOI Holloway June 2003 – June 2005 THERESA BURNS, SEXUAL HEALTH ADVISER Women’s Health.
INTERVENTIONS IN THE LESOTHO APPAREL INDUSTRY ALAFA KNOWLEDGE, ATTITUDE & PRACTICES PROGRESS & OUTCOMES REPORT IN 2012.
Mean HIV viral load among resident cases and undiagnosed in Oregon Jeff Capizzi, Epidemiologist Sean Schafer, HIV/STD/TB Medical Epidemiologist Lea Bush,
Why Late Diagnosis of HIV? Dr Faiza Khan Consultant in Public Health Kent County Council.
Africans and HIV in the UK: an epidemiological perspective May 2006 Valerie Delpech On behalf of the HIV Reporting Section with special thanks to Julia.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
Partner Notification Learning Outcomes At the end of this session you should be able to: Describe the aims of partner notification (PN)
What are you into? The role of social networking platforms in HIV risk behavior Darren Whitfield, MSW, Doctoral Student University of Denver, Graduate.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
“Its Different Now”: The Changing Landscape of HIV testing
The introduction of a universal blood borne virus (HIV, Hepatitis B and Hepatitis C) screening program on an 18 bed acute male inpatient psychiatric ward:
HPV vaccination for men
Latest update to the National Outbreak Response group on recent trends in HIV, STIs and Hepatitis among men who have sex with men (MSM) in Ireland June.
PEPSE* PRESCRIPTION IN THE EMERGENCY DEPARTMENT
HIV, STIs and Hepatitis among men who have sex with men (MSM) in Ireland October provisional data.
Presentation transcript:

Effective pre-test discussion? A case note review Mel Ottewill & Dr Zoe Warwick SSHA Conference 2008

Context HIV +ve patients still dying - non-adherence - late presentation Current national targets to reduce late presentation Within GU clinics by end % offer of HIV test - 60% uptake - 50% reduction in number of HIV infected people who remain unaware of their infection after their visit Changes in testing policy towards opt-out - CDC - WHO - BASHH/BHIVA/BIS review

BHIVA Audit 2006: Scenario leading to death Mortality audit BHIVA audit and Standards Sub-Committee 2006; accessible at Top bars: reclassified during audit Bottom bars: as initially reported

Late Diagnosis (MSM)

Local context Patient stay & morbidity & mortality

Late Presenters in Brighton last 100 admissions Number of admissions Bed days on Inpatient Unit 23% 37%

Local context Patient stay & morbidity & mortality National targets –100% offered –71.8% tested at first visit –78.2% either tested or had tested within the last year

Effect of knowing HIV status on sexual behaviour Meta-analysis of 11 study analyses –6 HIV+ “aware” versus HIV+ “unaware” –5 pre- and post- HIV seroconversion –rates of unprotected anal or vaginal intercourse UPI 53% (CI 45-60%) lower in those aware versus unaware of HIV+ status –If only considering where partner HIV-, 68% (59-76%) Marks, JAIDS, 2005

HIV Testing in GUM % accepting an HIV test % of HIV+ remaining undiagnosed after GUM visit

Are we effectively targeting our HIV testing? Anonymous sero-prevalence study (2004) of MSM - HIV prevalence within MSM=13.7% - 33% undiagnosed. Breakdown by GU attendance: - 78% of HIV +ve men in the community had attended a GU clinic in the last year -23.8% of GU attendees were HIV +ve -of whom 28.2% were undiagnosed - 5.4% of non-GU attendees were HIV +ve -of whom 54.5% were undiagnosed Dodds et al STI 2007

2005 audit of CNC HIV testing HIV test was offered to 76% of patients and was performed in 48% Men having sex with men accounted for 14% of the total visitors to CNC The rate of testing in MSM and low risk group were 53% and 15% respectively.

One year later……. Clinic targeting of high risk groups for HIV testing (Jan-Jun 2006) % of gay men have an HIV test on first visit % of non-whites had a test on the first visit But belonging to a high risk group doesn’t necessarily mean you’re high risk

Objectives To establish: –if risk assessment was adequate –If the response was appropriate according to the level of risk To identify common themes in reasons given for declining a test To suggest changes in practice to improve uptake of testing

Methodology Search database for MSM, Black African & IVDUs attending as a new episode between Jan- June 2006 who did not have an HIV test Included patients diagnosed HIV +ve in 2006 who had previously visited the CNC and left without an HIV test Agree level of risk (high, not-high) Review notes against a data collection tool Statistical analysis – Chi-squared

Results 259 new episode attendances at CNC belonging to high risk gps who did not test for HIV at that visit We reviewed 100 MSM case notes, all endemic and all IVDU Risk category –9 endemic; 98 MSM (2 coded incorrectly); 0 IVDU Age range 20-67; median 38

Results 12/107 had an HIV test within previous 3 mths - 7 high risk 5/107 had a HIV + partner since last test –None had had UPAI ie none high risk

Risks in those never tested before (n=21)

Risk in non-testers 43/107 (40%) assessed as being high risk according to sexual behaviour (all MSM)

STIs in non-testers Of the 107 All STIs were in MSM –7 had an STI since last test (but not at this visit) 5 low risk –13 had STI at that visit (but not since last HIV test) 9 low risk –12 had STI at this visit and since last test 7 low risk

STIs in high risk patients

PTD in high risk non-testers Of those assessed as high risk (43) –4 saw a HA All had a risk assessment, extensive pre-test discussion & reason for declining test documented 2/3 subsequently tested negative; 1/3 no subsequent test; 1 subsequently tested positive –39 did not see HA 31/39 had no documentation of extensive PTD 4/28 subsequently tested negative, 3 tested positive 8/39 had documentation of extensive PTD 4/8 subsequently tested negative

Documented reasons for declining –Perceived low risk (1 x high; 15 x low) –Not psychologically ready (5 x high; 7 x low) –Both of above (1 x high; 1 x low) –Tested within last 3 months (3 x high; 7 x low) –Wants fast test (2 x high; 0 x low) –Other (5 x high) 17/39 High risk patients with reason for declining test documented

Reasons for declining HIV test (where documented n=47)

Patients subsequently testing HIV Positive

AgeRisk at AV (behaviour) EPTD / HA / reason Visits between last HIV test and AV 1 36Not high      4 prior visits Never tested 2 43High      1 visit Last test Not high      Nil prior visits Last test 2003 (U) 1 visit post AV 4 45High      5 prior visits Never tested 5 24High      2 visits Last test: 2002, 2005 (U) 6 31High      No visits since last test (1 month before) and AV 7 39Not high      2 visits Last test 2002 (U) 1 visit post AV

Time between AV and + test Risk at + testHAEPTD 13 weekHigh  25 weeks POCHigh  310 mnths THTNA*NA 48 mnthsNot Doc*  51 mnthHigh*  68 mnthHigh*  74 mnthHigh 

Should the presence of an STI define a MSM as high risk? 7 non-testers subsequently tested HIV + 4 were defined as high risk according to behaviour 2 were defined as “not high” but did have an STI at that visit or since last test 6/7 (86%) would have been targeted for EPTD

Of the 52 “not high risk” according to behaviour –17 subsequently tested –ve –4 subsequently tested positive –31 had no subsequent test

Defining risk according to behaviour only Of the 34 in whom we have a HIV test result –13 individuals of would have been given EPTD. 3 of these tested +ve (23%), 10 –ve (77%) –21 individuals would not have been targeted for EPTD 4 of these tested +ve (19%), 17 tested –ve (81%)

Defining risk according to behaviour and presence of STI Of the 34 in whom we have a test result –24 would have been given EPTD 6 of these tested +ve (25%), 18 –ve (75%) –10 individuals would not have been targeted for EPTD 1 of these tested +ve (10%), 9 –ve (90%)

HIV positivity rate according to risk definition (%) Behaviour onlyBehaviour and STI EPTD2325 No EPTD1910

Messages Individualised EPTD positively determines future testing. Anyone defined as high risk according to reported sexual behaviour and those with STI at this visit or since last test should be targeted for EPTD.

Implications for Practice Accurate risk assessment and documentation Target EPTD to all high risk individuals –HA involvement ?Offer HA discussion ?Make routine in care pathway Spend time performing individualised PTD think HIV test at EVERY visit Address common barriers to testing

Undiagnosed HIV in MSM “A tale of 3 cities” LondonManchesterBrighton Number HIV+12%9%14% Unaware HIV+44%36%33% Unaware HIV+ and not accessed GUM 70%78%54% HIV-: UAI with unknown status 21%26%24% Dodds et al, STIs 2007 (e-pub;1/5/07) 69% accessed GUM in past 12 months

Proportion of GUM clinic attendees 1 accepting an HIV VCT and proportion leaving the clinic unaware of their infection by world region of birth 1 Previously undiagnosed HIV includes those diagnosed at the clinic attendance and those remaining undiagnosed. Data source: Unlinked Anonymous prevalence monitoring, England, Wales and Northern Ireland Proportion leaving clinic unaware of HIV-infection Proportion accepting VCT Born outside UKUK-bornBorn outside UKUK-born